Idiopathic Hypersomnia

Oncology·MeSH: Idiopathic Hypersomnia

Prevalence

30.0 / 100K

11 drugs in development·7 companies·11 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
LUMRYZ	Alkermes plc. (ALKS)

Phase 3(9)

Drug	Company
ALKS 2680	Alkermes plc. (ALKS)
FT218	AVADEL PHARMACEUTICALS PLC (AVDL)
hbs-301	IGM Biosciences, Inc. (IGMS)
kp1077	ZEVRA THERAPEUTICS, INC. (ZVRA)
pitolisant (Idiopathic Hypersomnia)	Harmony Biosciences Holdings, Inc. (HRMY)
pitolisant HD	Harmony Biosciences Holdings, Inc. (HRMY)
tak-360	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
tak-360	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
WAKIX (pitolisant) - Idiopathic Hypersomnia	Harmony Biosciences Holdings, Inc. (HRMY)

Phase 2/Phase 3(1)

Drug	Company
Alixorexton (ALKS 2680)	Alkermes plc. (ALKS)

BioSniper tracks 11 drugs in development for Idiopathic Hypersomnia across 7 companies.

There are 11 clinical trials targeting Idiopathic Hypersomnia tracked by BioSniper.

The estimated prevalence of Idiopathic Hypersomnia is approximately 30.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.